Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00779142 · ClinicalTrials.gov registry record · NA
Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies
A NA study, sponsored by Wake Forest University.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT00779142 is a NA study that was terminated before completion, run by Wake Forest University. The registered enrollment target is 2 participants.
The verdict
NCT00779142, a NA study, was terminated before completion, sponsored by Wake Forest University.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
It is well known that blindness is one of the most feared disabilities expressed by patients in the United States. Estimates of the economic impact of visual disability in the current population exceed 30 million US dollars in this country alone. The reasons for this figure are many; however age related macular degeneration (ARMD), diabetic retinopathy, glaucoma and uveitis are responsible for the majority of permanent visual disability and hence the costs in both quality of life and placing an economic burden on society. Research that may help reverse various abnormal biological responses that lead to or worsen clinical manifestations of diabetic retinopathy would be valuable.
Interventions
- DRUG Methotrexate intravenous 25mg/ml
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00779142
The ClinicalTrials.gov registry entry for NCT00779142 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Methotrexate intravenous 25mg/ml is the first listed.
NCT00779142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00779142 about?
NCT00779142 is a clinical study titled "Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies". It is well known that blindness is one of the most feared disabilities expressed by patients in the United States. Estimates of the economic impact of visual disability in the current population exceed 30 million US dollars in this country alone. The reasons for this figure are many; however age rel...
What is the current status of trial NCT00779142?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2011-09. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00779142?
The interventions under investigation include: Methotrexate intravenous 25mg/ml (DRUG).
Who is sponsoring clinical trial NCT00779142?
This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.